Insulin Pump Recall Leads To FDA Warning Letter For Medtronic
Executive Summary
The missive reflects quality systems issues at the Northridge, CA headquarters of Medtronic’s diabetes division. Analysts are split on what the warning letter’s long-term impact may be.
You may also be interested in...
Talking ATTD, 780G, Rumors And Missteps With Medtronic’s Diabetes Leaders
Medtech Insight spoke to the president of Medtronic’s diabetes business, Que Dallara, as well as two of the company’s medical affairs directors, about the company’s recently published data, and the timeline for the US launch of its 780G system.
Medtronic Insulin Pumps Vulnerable To Cybersecurity Attacks
Medtronic’s MiniMed series insulin pumps could allow unauthorized hackers to change the amount of insulin delivered to a patient, the FDA says.
Class-Action Suit Alleges Medtronic’s Rosy Forecast For MiniMed780G Misled Investors
The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.